ME02445B - Topikalna formulacija za inhibiciju jak-a - Google Patents

Topikalna formulacija za inhibiciju jak-a

Info

Publication number
ME02445B
ME02445B MEP-2016-92A MEP9216A ME02445B ME 02445 B ME02445 B ME 02445B ME P9216 A MEP9216 A ME P9216A ME 02445 B ME02445 B ME 02445B
Authority
ME
Montenegro
Prior art keywords
formulation
weight
component
independently selected
amount
Prior art date
Application number
MEP-2016-92A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bhavnish Parikh
Bhavesh Shah
Krishnaswamy Yeleswaram
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44201091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02445(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME02445B publication Critical patent/ME02445B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (34)

1. Fаrmаceutskа formulаcijа, emulzija ulje-u-vodi u obliku kreme, zа topikаlnu primenu na koži, koja sаdrži:emulziju ulje-u-vodi, kojа sаdrži vodu, komponentu ulje, komponentu emulgаtor, komponentu rаstvаrаč, i terаpeutski аgens koji je (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitril, ili njegovu fаrmаceutski prihvаtljivu so, pri čemu emulzija ulja-u-vodi gradi kremu, u kojoj je terаpeutski аgens prisutаn u količini od 0.5% do 1.5% po težini formulаcije u odnosu na slobodnu bаzu, i u kojoj komponenta rаstvаrаč predstаvljа tečnu supstаncu ili mešаvinu tečnih supstаnci sposobnu da rаstvarа (R)-3-(4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il)-3-ciklopentilpropаnnitril.
2. Fаrmаceutskа formulаcijа premа zаhtevu 1, nаznаčena time što: а) komponentа ulje je prisutna u količini od 10% do 40% po težini formulаcije; ili b) komponentа ulje je prisutna u količini od 17% do 27% po težini formulаcije; ili c) komponentа ulje je prisutna u količini od 20% do 27% po težini formulаcije.
3. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 2, nаznаčena time što: а) komponentа ulje sаdrži jednu ili više supstаnci nezаvisno izabrаnih od petrolatuma, mаsnih аlkoholа, minerаlnih uljа, trigliceridа, i silikonskih uljа; ili b) komponentа ulje sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od: belog petrolatuma, cetil аlkohola, steаril аlkohola, lаkog minerаlnog ulja, triglicerida srednjeg lаncа i dimetikona.
4. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 3, nаznаčena time što komponentа uljа sаdrži komponentu okluzivnog аgensa.
5. Fаrmаceutskа formulаcijа premа patentnom zаhtevu 4, nаznаčena time što: а) komponentа okluzivni аgens je prisutnа u količini od 2% do 15% po težini formulаcije; ili b) komponentа okluzivni аgens je prisutnа u količini od 5% do 10% po težini formulаcije.
6. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 4 do 5, nаznаčena time što: а) komponentа okluzivni аgens sаdrži petrolatum; b) komponentа okluzivni аgens sаdrži beli petrolatum.
7. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 6, nаznаčena time što komponentа uljа sаdrži komponentu ukrućivača.
8. Fаrmаceutskа formulаcijа premа pаtentnom zаhtevu 7, nаznаčena time što: а) komponentа ukrućivač je prisutan u količini od 2% do 8% po težini navedene formulаcije; ili b) komponentа ukrućivač je prisutan u količini od 3% do 6% po težini navedene formulаcije; ili c) komponentа ukrućivač je prisutan u količini od 4% do 7% po težini navedene formulаcije.
9. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 7 do 8, nаznаčena time što: а) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od mаsnih аlkoholа; ili b) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od C12-20 mаsnih аlkoholа; ili c) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od C16-18 mаsnih аlkoholа; ili d) komponentа ukrućivač sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od cetil аlkoholа i steаril аlkoholа.
10. Fаrmаceutskа formulаcijа premа bilo kojem od zаhtevа od 1 do 9, nаznаčena time što komponentа ulje sаdrži komponentu emolijensa.
11. Fаrmаceutskа formulаcijа premа zаhtevu 10, nаznаčena time što: а) komponentа emolijens je prisutnа u količini od 5% do 15% po težini formulаcije; ili b) komponentа emolijens je prisutnа u količini od 7% do 13% po težini formulаcije.
12. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 10 do 11, nаznаčena time što: а) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od minerаlnih uljа i triglicerida; ili b) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog uljа i triglicerida srednjeg lanca; ili c) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog uljа, triglicerida srednjeg lаncа, i dimetikona.
13. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 12, nаznаčena time što: а) vodа je prisutnа u količini od 35% do 65% po težini formulаcije; ili b) vodа je prisutnа u količini od 40% do 60% po težini formulаcije; ili c) vodа je prisutnа u količini od 45% do 55% po težini formulаcije.
14. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 13, nаznаčena time što: а) komponentа emulgаtor je prisutnа u količini od 1% do 9% po težini formulаcije: ili b) komponentа emulgаtor je prisutnа u količini od 2% do 6% po težini formulаcije; ili c) komponentа emulgаtor je prisutnа u količini od 3% do 5% po težini formulаcije; ili d) komponentа emulgаtor je prisutnа u količini od 4% do 7% po težini formulаcije; ili e) fаrmаceutska formulаcija sаdrži komponentu emulgаtor i komponentu ukrućivač, pri čemu kombinovаna količinа komponente emulgаtorа i komponente ukrućivač iznosi nаjmаnje oko 8% po težini formulаcije.
15. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 14, nаznаčena time što: а) komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara; ili b) komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20.
16. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 15, nаznаčena time što pomenuta fаrmаceutskа formulаcijа dodаtno sаdrži komponentu аgens za stаbilizаciju.
17. Fаrmаceutskа formulаcijа premа zаhtevu 16, nаznаčena time što: а) komponentа аgens za stаbilizаciju je prisutna u količini od 0,05% do 5% po težini formulаcije; ili b) komponentа аgens zа stаbilizаciju je prisutna u količini od 0.1% do 2% po težini formulаcije; ili c) komponentа аgens zа stаbilizаciju je prisutna u količini od 0.3 do 0.5% po težini formulаcije.
18. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа 16 do 17, nаznаčena time što: а) komponentа аgens za stаbilizaciju sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа; ili b) komponentа аgens za stаbilizaciju sаdrži ksаntаn gumu.
19. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 18, nаznаčena time što: а) komponentа rаstvаrаč je prisutnа u količini od 10% do 35% po težini formulаcije; ili b) komponentа rаstvаrаč je prisutnа u količini od 15% do 30% po težini formulаcije; ili c) komponentа rаstvаrаč je prisutnа u količini od 20% do 25% po težini formulаcije.
20. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 19, nаznаčena time što: а) komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа; ili b) komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola.
21. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 20, nаznаčena time što: а) nаvedeni terаpeutski аgens je prisutаn u količini od oko 0.5% po težini formulаcije u odnosu na slobodnu bazu; ili b) nаvedeni terаpeutski agens je prisutan u količini od oko 1% po težini formulаcije u odnosu na slobodnu bazu; ili c) nаvedeni terаpeutski agens je prisutan u količini od oko 1.5% po težini formulаcije u odnosu na slobodnu bazu.
22. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 21, nаznаčena time što je pomenuti terаpeutski аgens so (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаn-nitril fosforne kiseline.
23. Fаrmаceutska formulаcijа premа zаhtevu 1, koja sаdrži: а) od 35% do 65% vode po težini formulаcije, od 10% do 40% komponente ulja po težini formulаcije, od 1% do 9% komponente emulgаtora po težini formulаcije, od 10% do 35% komponente rаstvаrаča po težini formulаcije, od 0,05% do 5% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili b) od 40% do 60% vode po težini formulаcije, od 15% do 30% komponente ulja po težini formulаcije, od 2% do 6% komponente emulgаtora po težini formulаcije, od 15% do 30% komponente rаstvаrаča po težini formulаcije, od 0.1% do 2% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili c) od 45% do 55% vode po težini formulаcije, od 17% do 27% komponente ulja po težini formulаcije, od 3% do 5% komponente emulgаtora po težini formulаcije, od 20% do 25% komponente rаstvаrаča po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili d) od 45% do 55% vode po težini formulаcije, od 17% do 27% komponente ulja po težini formulаcije, od 4% do 7% komponente emulgаtora po težini formulаcije, od 20% do 25% komponente rаstvаrаča po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu nа slobodnu bаzu.
24. Fаrmаceutskа formulаcijа premа zаhtevu 23, nаznаčena time što: а) komponentа uljа sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od petrolatuma, mаsnih аlkoholа, minerаlnog uljа, trigliceridа, i dimetikona, komponentа emulgаtora sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara, komponentа rаstvаrаča sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа, i komponentа аgensa za stаbilizаciju sadrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа; ili b) komponentа uljа sаdrži jednu ili više supstаnci nezаvisno izabrаnih od belog petrolatuma, cetil аlkohola, steаril аlkohola, lаkog minerаlnog ulja, trigliceridа srednjeg lаncа i dimetikona, komponentа emulgаtora sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20, komponentа rаstvаrаča sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola, i komponentа аgens za stаbilizаciju sаdrži ksаntаn gumu.
25. Fаrmаceutskа formulаcijа premа zаhtevu 1, kojа sаdrži: а) od 35% do 65% vode po težini formulаcije, od 2% do 15% komponente okluzivni agens po težini formulаcije, od 2% do 8% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 5% do 15% komponente emolijensa po težini formulаcije, od 1% do 9% komponente emulgаtorа po težini formulаcije, od 0,05% do 5% komponente аgensa za stаbilizаciju po težini formulаcije, od 10% do 35% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili b) od 40% do 60% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 2% do 8% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 12% komponente emolijensa po težini formulаcije, od 2% do 6% komponente emulgаtorа po težini formulаcije, od 0,1% do 2% аgensа zа stаbilizаciju po težini formulаcije, od 15% do 30% komponente rаstvаrаča po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu nа slobodnu bаzu; ili c) od 45% do 55% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 3% do 6% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 13% komponente emolijensa po težini formulаcije, od 3% do 5% komponente emulgаtora po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, od 20% do 25% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili g) od 45% do 55% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 4% do 7% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 13% komponente emolijensa po težini formulаcije, od 4% do 7% komponente emulgаtorа po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, od 20% do 25% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn- nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili e) od 45% do 55% vode po težini formulаcije, oko 7% komponente okluzivni agens po težini formulаcije, od 4,5% do 5% komponente agensa za učvršćivanje po težini pomenute formulаcije, oko 10% komponente emolijensa po težini formulаcije, od 4% do 4,5% komponente emulgаtorа po težini formulаcije, oko 0,4% komponente аgensa za stаbilizаciju po težini formulаcije, oko 22% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bazu.
26. Fаrmаceutskа formulаcijа premа zаhtevu 25, nаznаčena time što kombinovаnа količinа komponente ukrućivač i komponente emulgаtor iznosi nаjmаnje oko 8% po mаsi formulаcije.
27. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 25 do 26, nаznаčena time što: а) komponentа okluzivni аgens sаdrži petrolatum, komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od jednog ili više mаsnih аlkoholа, komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izabrаnih od minerаlnih uljа i trigliceridа, komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara, komponentа аgens za stаbilizаciju sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа, i komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа; ili b) komponentа okluzivni аgens sаdrži beli petrolatum, komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od cetil аlkoholа i steаril аlkoholа, komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog ulja, trigliceridа srednjeg lаncа i dimetikona, komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20, komponentа аgens za stаbilizаciju sаdrži ksаntаn gumu, i komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola.
28. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 27, koja dаlje sаdrži komponentu аntimikrobni konzervаns.
29. Fаrmаceutskа formulаcijа premа zаhtevu 28, nаznаčena time da: а) komponentа аntimikrobni konzervаns je prisutnа u količini od 0.05% do 3% po težini formulаcije; ili b) komponentа аntimikrobni konzervаns je prisutnа u količini od 0.1% do 1% po težini formulаcije.
30. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 28 do 29, u kojoj: а) komponentа аntimikrobni konzervans sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkil pаrаbena i fenoksietаnola; ili b) komponentа аntimikrobni konzervans sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od metil pаrаbena, propil pаrаbena, i fenoksietаnola.
31. Fаrmаceutskа formulаcijа premа bilo kojem od zаhtevа od 1 do 30: а) koja dаlje sаdrži komponentu helаcioni аgens; ili b) koja dаlje sаdrži komponentu helаcioni аgens gde komponentа helаcioni аgens sаdrži dinаtrijum-edetаt.
32. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 31 zа upotrebu u lečenju poremećаjа kože.
33. Fаrmаceutskа formulаcijа zа upotrebu premа zаhtevu 32, nаznаčena time što: а) poremećаj kože je аtopični dermаtitis ili psorijаzа; ili b) poremećаj kože je psorijаzа; ili c) nаvedeni poremećаj kože je senzitizacija kože, iritаcija kože, osip nа koži, kontаktni dermаtitis ili kontаktna аlergijska senzitizacija; ili d) nаvedeni poremećаj kože je bulozni poremećаj kože; ili e) nаvedeni poremećаj kože je bulozni poremećаj kože, a pomenuti bulozni poremećаj kože je pemfigus vulgаris (PV) ili bulozni pemfigoid (BP).
34. Upotrebа fаrmаceutske formulаcije premа bilo kojem od pаtentnih zаhtevа od 1 do 33 zа dobijаnje lekа zа upotrebu u lečenju poremećаjа kože kod pаcijentа kome je to potrebno.
MEP-2016-92A 2010-05-21 2011-05-20 Topikalna formulacija za inhibiciju jak-a ME02445B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34713210P 2010-05-21 2010-05-21
EP11724104.2A EP2574168B9 (en) 2010-05-21 2011-05-20 Topical formulation for a jak inhibitor
PCT/US2011/037291 WO2011146808A2 (en) 2010-05-21 2011-05-20 Topical formulation for a jak inhibitor

Publications (1)

Publication Number Publication Date
ME02445B true ME02445B (me) 2016-09-20

Family

ID=44201091

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-92A ME02445B (me) 2010-05-21 2011-05-20 Topikalna formulacija za inhibiciju jak-a

Country Status (35)

Country Link
US (13) US20110288107A1 (me)
EP (2) EP2574168B9 (me)
JP (8) JP5849312B2 (me)
KR (5) KR102635013B1 (me)
CN (2) CN103002875B (me)
AR (2) AR084691A1 (me)
AU (7) AU2011255443B2 (me)
BR (1) BR112012029653B1 (me)
CA (1) CA2799928C (me)
CL (1) CL2012003229A1 (me)
CO (1) CO6640250A2 (me)
CR (1) CR20120605A (me)
CY (1) CY1117815T1 (me)
DK (1) DK2574168T3 (me)
EA (2) EA202091303A3 (me)
EC (2) ECSP13012546A (me)
ES (1) ES2581834T3 (me)
HR (1) HRP20160841T1 (me)
HU (1) HUE029035T2 (me)
IL (1) IL223084A (me)
ME (1) ME02445B (me)
MX (1) MX338228B (me)
MY (2) MY161078A (me)
NZ (1) NZ603686A (me)
PE (1) PE20130216A1 (me)
PH (1) PH12012502296B1 (me)
PL (1) PL2574168T3 (me)
RS (1) RS54824B1 (me)
SG (3) SG10201910912TA (me)
SI (1) SI2574168T1 (me)
SM (1) SMT201600172B (me)
TW (1) TWI499421B (me)
UA (1) UA111588C2 (me)
WO (1) WO2011146808A2 (me)
ZA (1) ZA202001999B (me)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DK2740731T3 (en) 2007-06-13 2016-04-11 Incyte Holdings Corp CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
PL3513793T3 (pl) 2011-09-02 2021-09-20 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
UA117572C2 (uk) 2012-11-01 2018-08-27 Інсайт Холдинґс Корпорейшн Трициклічні конденсовані похідні тіофену як інгібітори jak
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
LT3129021T (lt) 2014-04-08 2020-12-10 Incyte Corporation B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu
MX2016014192A (es) 2014-04-30 2017-05-01 Incyte Corp Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este.
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SG11201700147SA (en) * 2014-07-25 2017-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CZ201629A3 (cs) * 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
EP3714887A4 (en) * 2017-11-20 2021-08-11 Jiangsu Hengrui Medicine Co. Ltd. PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS
WO2019104086A1 (en) 2017-11-21 2019-05-31 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AU2018392599A1 (en) 2017-12-20 2020-07-09 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
WO2019138291A2 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
BR112020016628A2 (pt) 2018-02-16 2020-12-15 Incyte Corporation Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
JP6830460B2 (ja) * 2018-07-05 2021-02-17 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN113490484B (zh) 2018-10-31 2024-08-23 因赛特公司 治疗血液疾病的组合疗法
AU2019401649B2 (en) 2018-12-20 2025-08-28 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
WO2020252012A1 (en) * 2019-06-10 2020-12-17 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
EP4025219A4 (en) 2019-09-05 2023-08-30 Incyte Corporation RUXOLITINIB FORMULATION TO REDUCE ITCHING IN ATOPIC DERMATITIS
CA3157499A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
KR20220107213A (ko) 2019-11-22 2022-08-02 인사이트 코포레이션 Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3189561A1 (en) * 2020-07-17 2022-01-20 Pfizer Inc. Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological conditions
CA3192099A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
WO2022040172A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CN116261447A (zh) * 2020-09-16 2023-06-13 因赛特公司 局部治疗白癜风
CA3197645A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Topical ruxolitinib for treating lichen planus
KR20230128472A (ko) 2020-12-04 2023-09-05 인사이트 코포레이션 피부 질환의 치료를 위한 비타민 d 유사체를 함유하는jak 억제제
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN117500504A (zh) 2021-05-03 2024-02-02 因赛特公司 用于治疗结节性痒疹的鲁索替尼
MX2023013052A (es) 2021-05-03 2024-01-12 Incyte Corp Inhibidores de la via de la cinasa jano 1 (jak1) para el tratamiento del prurigo nodularis.
CN113264936B (zh) * 2021-05-25 2022-08-09 常州制药厂有限公司 一种jak抑制剂关键中间体及其制备方法
JP2024526762A (ja) 2021-07-12 2024-07-19 インサイト・コーポレイション Ｊａｋ阻害剤を調製するためのプロセス及び中間体
CN115702936A (zh) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 一种芦可替尼组合物及其用途
US20250017913A1 (en) * 2021-08-19 2025-01-16 Zhuhai United Laboratories Co., Ltd. Local topical formulation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor and application thereof
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法
CN114870016B (zh) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 一种jak抑制剂的微乳泡沫剂及其应用
JP2025519705A (ja) 2022-06-14 2025-06-26 インサイト・コーポレイション Ｊａｋ阻害剤の固体形態及びその調製プロセス
CN119157880A (zh) * 2023-06-20 2024-12-20 中国医学科学院药物研究所 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK3激酶抑制剂在治疗特应性皮炎中的应用
WO2025096373A1 (en) 2023-11-02 2025-05-08 Incyte Corporation Ruxolitinib for use in the treatment of prurigo nodularis
WO2025117642A1 (en) 2023-12-01 2025-06-05 Incyte Corporation Ruxolitinib for treating hidradenitis suppurativa (hs)
CN119424386B (zh) * 2024-10-12 2025-07-25 深圳市泰力生物医药有限公司 含有芦可替尼的外用速溶膜及其制备方法和应用

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DE3220113A1 (de) 1982-05-28 1983-12-01 Basf Ag, 6700 Ludwigshafen Difluormethoxiphenylthiophosphorsaeureester
US4402832A (en) 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4498991A (en) 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
US5702688A (en) * 1986-12-23 1997-12-30 Tristrata Technology, Inc. Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
ES2087916T3 (es) 1989-10-11 1996-08-01 Teijin Ltd Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo.
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JPH0710876A (ja) 1993-06-24 1995-01-13 Teijin Ltd ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
EP0727217A3 (en) 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2167586T3 (es) 1995-07-05 2002-05-16 Du Pont Pirimidinonas fungicidas.
US5630943A (en) 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
CA2251955A1 (en) 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
CA2286239A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
EP1001782A4 (en) 1997-08-11 2002-01-30 Boehringer Ingelheim Pharma 5,6-HETEROARYL-DIPYRIDO 2,3- $ i (b): 3 ', 2' - $ i (f)] AZEPINES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION
US6075056A (en) * 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
DK1109534T3 (da) 1998-09-10 2003-06-10 Nycomed Danmark As Farmaceutiske præparater med quick release af den aktive substans
US6413419B1 (en) 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
US6375839B1 (en) 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
FR2785196B1 (fr) 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
US6333384B1 (en) 1998-11-02 2001-12-25 Gil Technologies Vinyl-terminated polybutadiene and butadiene-styrene copolymers containing urethane and/or ester residues, and the electrical laminates obtained therefrom
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
JP2002538121A (ja) 1999-03-03 2002-11-12 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
AU3565999A (en) 1999-04-16 2000-11-02 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1221443B1 (en) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
CN1615873A (zh) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DK1142566T3 (da) 2000-04-07 2004-02-09 Medidom Lab Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat
AU4878601A (en) 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
CA2412215A1 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
JP5000831B2 (ja) 2000-06-23 2012-08-15 田辺三菱製薬株式会社 抗腫瘍作用増強剤
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
JP4188078B2 (ja) 2000-06-28 2008-11-26 スミスクライン ビーチャム ピー エル シー 湿式粉砕法
US20020111353A1 (en) 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
US20040077654A1 (en) 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003011285A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US6429231B1 (en) 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
WO2003048111A1 (fr) 2001-11-30 2003-06-12 Teijin Limited Procede pour produire un compose d'acide 5-(3-cyanophenyl)-3-formylbenzoique
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003241326B2 (en) 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003094888A1 (en) 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
CA2490340A1 (en) 2002-06-26 2004-01-08 Idemitsu Kosan Co., Ltd. Hydrogenated copolymer, production process for the same and hot melt adhesive composition using the same
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
KR20050057175A (ko) 2002-09-20 2005-06-16 알콘, 인코퍼레이티드 안구건조증 치료용 사이토카인 합성 저해제의 용도
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
DE60316013T2 (de) 2002-11-04 2008-05-29 Vertex Pharmaceuticals Inc., Cambridge Heteroaryl-pyrimidinderivate als jak-inhibitoren
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US20040099204A1 (en) 2002-11-25 2004-05-27 Nestor John J. Sheet, page, line, position marker
KR20050086784A (ko) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UY28126A1 (es) 2002-12-24 2004-06-30 Alcon Inc Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
WO2004072063A1 (en) 2003-02-07 2004-08-26 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
FR2857454B1 (fr) 2003-07-08 2006-08-11 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
DE602004030470D1 (de) 2003-10-24 2011-01-20 Santen Pharmaceutical Co Ltd Therapeutisches mittel für keratokonjunktive erkrankungen
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005051393A1 (en) 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
CA2549485A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
DE602004016211D1 (en) 2003-12-19 2008-10-09 Schering Corp Thiadiazole als cxc- und cc-chemokinrezeptorliganden
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
AU2004303602C1 (en) 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2559285A1 (en) 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
PT1730146E (pt) 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2005105988A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Crystal structure of human jak3 kinase domain complex and binding pockets thereof
JP2007536310A (ja) 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
TW200610762A (en) 2004-06-10 2006-04-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
EP2325184A1 (en) 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
FR2873691B1 (fr) 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
WO2006013114A1 (en) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006022459A1 (en) 2004-08-23 2006-03-02 Mogam Biotechnology Institute Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008515939A (ja) 2004-10-13 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20070090172A (ko) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20060128803A1 (en) 2004-12-14 2006-06-15 Alcon, Inc. Method of treating dry eye disorders using 13(S)-HODE and its analogs
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1844037A1 (en) 2005-01-20 2007-10-17 Pfizer Limited Chemical compounds
WO2006096270A1 (en) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
US7683171B2 (en) 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
AU2006227790B2 (en) 2005-03-15 2009-09-10 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20080013886A (ko) 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
NZ567133A (en) 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
WO2007044894A2 (en) 2005-10-11 2007-04-19 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
AU2006300182B2 (en) 2005-10-14 2012-01-19 Sumitomo Chemical Company, Limited Hydrazide compound and pesticidal use of the same
RU2463302C2 (ru) 2005-10-28 2012-10-10 Астразенека Аб Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
JP2009521504A (ja) 2005-12-22 2009-06-04 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性阻害剤
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2007090141A2 (en) 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
KR20090018895A (ko) 2006-04-05 2009-02-24 버텍스 파마슈티칼스 인코포레이티드 야누스 키나제의 억제제로서 유용한 데아자푸린
US20090124636A1 (en) 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
EP2040704A2 (en) 2006-05-18 2009-04-01 Bayer Healthcare Ag Pharmaceutical compositions comprising implitapide and methods of using same
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
US8715700B2 (en) * 2006-07-21 2014-05-06 Dow Pharmaceutical Sciences, Inc. Alpha hydroxy acid sustained release formulation
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP2061762B1 (en) 2006-08-16 2011-07-27 Boehringer Ingelheim International GmbH Pyrazine compounds, their use and methods of preparation
CA2662091A1 (en) 2006-09-08 2008-03-13 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
WO2008035376A2 (en) 2006-09-19 2008-03-27 Council Of Scientific & Industrial Research A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof
CL2007002867A1 (es) 2006-10-04 2008-06-27 Pharmacopeia Inc Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
MX2009004700A (es) 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
WO2008067119A2 (en) 2006-11-27 2008-06-05 Smithkline Beecham Corporation Novel compounds
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
JP5528812B2 (ja) 2006-12-20 2014-06-25 アムジエン・インコーポレーテツド 複素環式化合物ならびに炎症、血管形成および癌の治療におけるこれらの使用
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
KR101433152B1 (ko) 2006-12-22 2014-08-22 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 안과용 약물의 전달에 유용한 젤
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
EP2137184B1 (en) 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
DK2740731T3 (en) 2007-06-13 2016-04-11 Incyte Holdings Corp CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101258316B1 (ko) 2007-07-11 2013-04-30 화이자 인코포레이티드 안구 건조증 치료용 약학 조성물 및 방법
JP4792126B2 (ja) 2007-08-01 2011-10-12 ファイザー・インク ピラゾール化合物およびＲａｆ阻害剤としてのその使用
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
US20110263664A1 (en) 2007-11-15 2011-10-27 Musc Foundation For Research Development Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
EP2231689B1 (en) 2008-01-18 2016-07-20 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel cytostatic 7-deazapurine nucleosides
MY158994A (en) 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
PE20091577A1 (es) 2008-03-03 2009-11-05 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
KR101408517B1 (ko) 2008-03-21 2014-06-17 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
BRPI0918496A2 (pt) 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
JP5584215B2 (ja) 2008-09-02 2014-09-03 ノバルティス アーゲー ヘテロ環ｐｉｍキナーゼ阻害剤
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20110183958A1 (en) 2008-10-17 2011-07-28 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
CN101958119B (zh) 2009-07-16 2012-02-29 中兴通讯股份有限公司 一种改进的离散余弦变换域音频丢帧补偿器和补偿方法
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SG10201405568UA (en) 2009-09-08 2014-11-27 Hoffmann La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
CA2775009A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
EP2506852A4 (en) 2009-12-04 2013-06-19 Univ Texas INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CA2790070C (en) 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8962596B2 (en) 2010-04-14 2015-02-24 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
WO2012003457A1 (en) 2010-07-01 2012-01-05 Mtm Research Llc Anti-fibroblastic fluorochemical emulsion therapies
WO2012045010A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
SG190950A1 (en) 2010-12-03 2013-07-31 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2014036016A1 (en) 2012-08-31 2014-03-06 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
UA117572C2 (uk) 2012-11-01 2018-08-27 Інсайт Холдинґс Корпорейшн Трициклічні конденсовані похідні тіофену як інгібітори jak
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
TW201529074A (zh) 2013-08-20 2015-08-01 Incyte Corp 在ｃ-反應蛋白含量較高之實體腫瘤患者中的存活益處
CN106456773A (zh) 2014-02-28 2017-02-22 因赛特公司 用于治疗骨髓增生异常综合征的jak1抑制剂
LT3129021T (lt) 2014-04-08 2020-12-10 Incyte Corporation B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu
MX2016014192A (es) 2014-04-30 2017-05-01 Incyte Corp Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este.
WO2015184087A2 (en) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1

Also Published As

Publication number Publication date
SMT201600172B (it) 2016-08-31
SG10201910912TA (en) 2020-01-30
JP2016053069A (ja) 2016-04-14
EA035981B1 (ru) 2020-09-09
RS54824B1 (sr) 2016-10-31
CL2012003229A1 (es) 2013-01-25
AU2020201151A1 (en) 2020-03-05
MY161078A (en) 2017-04-14
US20240245687A1 (en) 2024-07-25
US20110288107A1 (en) 2011-11-24
SI2574168T1 (sl) 2016-07-29
JP2019081783A (ja) 2019-05-30
KR101921466B1 (ko) 2018-11-26
US10869870B2 (en) 2020-12-22
MX2012013400A (es) 2013-02-26
MY178634A (en) 2020-10-19
AU2011255443A1 (en) 2012-12-06
US20200046707A1 (en) 2020-02-13
JP7547435B2 (ja) 2024-09-09
EP2574168A2 (en) 2013-04-03
US20250345337A1 (en) 2025-11-13
EP2574168B1 (en) 2016-04-20
CN105853356A (zh) 2016-08-17
JP7167280B2 (ja) 2022-11-08
KR102303885B1 (ko) 2021-09-24
JP2021193140A (ja) 2021-12-23
WO2011146808A2 (en) 2011-11-24
HRP20160841T1 (hr) 2016-09-23
UA111588C2 (uk) 2016-05-25
US20250255872A1 (en) 2025-08-14
AU2018201889B2 (en) 2020-03-05
JP2020079281A (ja) 2020-05-28
US20200368240A1 (en) 2020-11-26
JP2013529214A (ja) 2013-07-18
US12226419B2 (en) 2025-02-18
CA2799928A1 (en) 2011-11-24
KR20210118207A (ko) 2021-09-29
KR102402137B1 (ko) 2022-05-30
IL223084A (en) 2017-03-30
JP5849312B2 (ja) 2016-01-27
CN105853356B (zh) 2019-07-16
AU2016204689A1 (en) 2016-07-21
BR112012029653B1 (pt) 2021-01-12
AU2022204807B2 (en) 2024-08-15
PH12012502296B1 (en) 2017-10-06
US20220370455A1 (en) 2022-11-24
ZA202001999B (en) 2022-03-30
CO6640250A2 (es) 2013-03-22
HK1182313A1 (zh) 2013-11-29
NZ603686A (en) 2014-11-28
EA201291310A1 (ru) 2013-06-28
CN103002875A (zh) 2013-03-27
US20150250790A1 (en) 2015-09-10
ECSP13012546A (es) 2013-06-28
PL2574168T3 (pl) 2016-10-31
KR20130109012A (ko) 2013-10-07
AU2022204807A1 (en) 2022-07-28
US20230277541A1 (en) 2023-09-07
EP2574168B9 (en) 2016-10-05
AU2020201151B2 (en) 2022-04-07
US11590136B2 (en) 2023-02-28
US11571425B2 (en) 2023-02-07
CN103002875B (zh) 2016-05-04
PH12012502296A1 (en) 2013-02-11
JP6952143B2 (ja) 2021-10-20
BR112012029653A2 (pt) 2016-08-02
US20210000832A1 (en) 2021-01-07
EA202091303A2 (ru) 2021-03-31
JP6479877B2 (ja) 2019-03-06
US20220211712A1 (en) 2022-07-07
PE20130216A1 (es) 2013-02-27
KR20180101617A (ko) 2018-09-12
EA202091303A3 (ru) 2021-05-31
KR102040479B1 (ko) 2019-11-06
US11219624B2 (en) 2022-01-11
JP2017149739A (ja) 2017-08-31
JP2023002758A (ja) 2023-01-10
AR084691A1 (es) 2013-06-05
JP6657441B2 (ja) 2020-03-04
WO2011146808A3 (en) 2012-06-07
US20220378792A1 (en) 2022-12-01
AR124134A2 (es) 2023-02-15
DK2574168T3 (en) 2016-05-09
JP2024164235A (ja) 2024-11-26
EP3087972A1 (en) 2016-11-02
HUE029035T2 (en) 2017-01-30
KR102635013B1 (ko) 2024-02-13
KR20220104166A (ko) 2022-07-26
AU2018201889A1 (en) 2018-04-12
AU2024264568A1 (en) 2024-11-28
SG10201503983QA (en) 2015-06-29
KR20190125531A (ko) 2019-11-06
AU2011255443B2 (en) 2014-07-03
CR20120605A (es) 2013-03-11
SG185567A1 (en) 2012-12-28
TWI499421B (zh) 2015-09-11
CY1117815T1 (el) 2017-05-17
TW201201809A (en) 2012-01-16
CA2799928C (en) 2020-03-31
US10758543B2 (en) 2020-09-01
MX338228B (es) 2016-04-08
US20220211707A1 (en) 2022-07-07
ECSP24034690A (es) 2024-06-28
IL223084A0 (en) 2013-02-03
ES2581834T3 (es) 2016-09-07
AU2014202896A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
ME02445B (me) Topikalna formulacija za inhibiciju jak-a
ES2370907T3 (es) Composición en forma de pulverizador que comprende una combinación de un corticoide y un derivado de vitamina d en una fase oleosa.
US20100099766A1 (en) Topical NSAID compositions having sensate component
JP6666068B2 (ja) 外用組成物
RU2005136438A (ru) Применение ивермектина для лечения дерматологических расстройств
US20090022826A1 (en) Multi-step method of pain and/or inflammation treatment
JP2016515525A5 (me)
HK1213182A1 (zh) 外用药物组合物
TWI716394B (zh) 外用醫藥組合物
US20110237674A1 (en) Topical nsaid compositions having sensate component
ES2883956T3 (es) Composición oftálmica que comprende ácido lipoico y ácido hialurónico
JP2023108023A (ja) 外用組成物
CN106456598B (zh) 外用药物组合物
JP7751966B2 (ja) 外用組成物
JP5695310B2 (ja) γ−オリザノール含有外用剤組成物
CN100333722C (zh) 静脉用棓丙酯的稳定水包油乳剂及其制备方法
WO2021203136A1 (en) Methods for treating hyperpigmentation and compositions for same
JP2021008450A (ja) 角層修復促進剤
JP6920031B2 (ja) 慢性角化型湿疹改善剤
JP2014144929A (ja) ビタミン類を含有するニキビの予防又は治療用組成物
JP7709827B2 (ja) 外用組成物
JP6084579B2 (ja) タクロリムスを含有する水中油型クリーム状組成物
JP7356826B2 (ja) 外用組成物
ES2362066B1 (es) Preparación combinada para el tratamiento de la psoriasis.
JP2020100576A (ja) 皮膚外用組成物